World Wires · story 31757 · unverified · 1 source(s)

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

New Phase 3 Data Demonstrates Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

Open in the desk

Coverage

• Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures GlobeNewswire: public companies · tier D · clear net · 2026-10-09 08:00 UTC

What this site indexes